On the Terminal Homologation of Physiologically Active Peptides as a Means of Increasing Stability in Human Serum – Neurotensin, Opiorphin, B27‐KK10 Epitope, NPY
- 10 May 2011
- journal article
- research article
- Published by Wiley in Chemistry & Biodiversity
- Vol. 8 (5) , 711-739
Abstract
The terminal homologation by CH2insertion into the peptides mentioned in the title is described. This involves replacement of theN‐terminal amino acid residue by aβ2‐ and of theC‐terminal amino acid residue by aβ3‐homo‐amino acid moiety (β2hXaa andβ3hXaa, resp.;Fig. 1). In this way, the structure of the peptide chain from the N‐terminal to the C‐terminal stereogenic center is identical, and the modified peptide is protected against cleavage by exopeptidases (Figs. 2and3). Neurotensin (NT;1) and its C‐terminal fragment NT(8–13) are ligands of the G‐protein‐coupled receptors (GPCR) NT1, NT2, NT3, and NT analogs are promising tools to be used in cancer diagnostics and therapy. The affinities of homologated NT analogs,2b–2e, for NT1 and NT2 receptors were determined by using cell homogenates and tumor tissues (Table 1); in the latter experiments, the affinities for the NT1 receptor are more or less the same as those of NT (0.5–1.3vs.0.6 nM). At the same time, one of the homologated NT analogs,2c, survives in human plasma for 7 days at 37° (Fig. 6). An NMR analysis of NT(8–13) (Tables 2and4, andFig. 8) reveals that this N‐terminal NT fragment folds to a turn in CD3OH. – In the case of the human analgesic opiorphin (3a), a pentapeptide, and of the HIV‐derived B27‐KK10 (4a), a decapeptide, terminal homologation (→3band4b, resp.) led to a 7‐ and 70‐fold half‐life increase in plasma (Fig. 9). With N‐terminally homologated NPY,5c, we were not able to determine serum stability; the peptide consisting of 36 amino acid residues is subject to cleavage by endopetidases. Three of the homologated compounds,2b, 2c, and5c, were shown to be agonists (Fig. 7and11). A comparison of terminal homologation with other stability‐increasing terminal modifications of peptides is performed (Fig. 5), and possible applications of the neurotensin analogs, described herein, are discussed.Keywords
This publication has 131 references indexed in Scilit:
- Pyrrolinone-Based Peptidomimetics.“Let the Enzyme or Receptor be the Judge”Accounts of Chemical Research, 2010
- Kinetic Study of Neuropeptide Y (NPY) Proteolysis in Blood and Identification of NPY3–35Journal of Biological Chemistry, 2009
- Constitutive Dimerization of the G-Protein Coupled Receptor, Neurotensin Receptor 1, Reconstituted into Phospholipid BilayersBiophysical Journal, 2009
- Peptides and peptidomimetics as prototypesCurrent Opinion in Chemical Biology, 2008
- Interplay among side chain sequence, backbone composition, and residue rigidification in polypeptide folding and assemblyProceedings of the National Academy of Sciences, 2008
- Foldamers with Heterogeneous BackbonesAccounts of Chemical Research, 2008
- Design and in Vitro Characterization of Highly sst2-Selective Somatostatin Antagonists Suitable for RadiotargetingJournal of Medicinal Chemistry, 2008
- Peptidomimetics, a synthetic tool of drug discoveryCurrent Opinion in Chemical Biology, 2008
- Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathwaysProceedings of the National Academy of Sciences, 2006
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973